New possibilities for the future
Progenicyte Japan is a venture company aiming at the commercialization of a small molecule compound to increase endogenous stem cells, which was developed by Dr. Kiminobu Sugaya and his research group. Dr. Sugaya is a professor and head of neuroscience at the University of Central Florida, College of Medicine, located in Florida, USA. In our company, peoples with a variety of expertise in different fields are working hard together to reach our goal, which is to bring innovative technologies from the bench to the world.
OUTLINE
Company
name: PROGENICYTE
JAPAN CO., LTD.
Founding Date : January 24, 2020
Capital : 7.5 million yen
Address : Kobe International Conference Center S606
6-9-1 Minatojima Nakamachi, Chuo-ward
Kobe-city, Hyogo 650-0046, Japan
URL : https://www.progenicyte.com
OUR TEAM
Co-founder
Co Representative Director
Kiminobu Sugaya, PhD
Professor
and Head of Neuroscience, University of
central Florida
Visiting Professor, Clinical Research, Innovation and Education Center,
Tohoku University Hospital
Honorary Professor, The University of United Arab Emirates, Al-Ain, UEA
Honorary Professor, Instituto de Investigaciones Científicas y Servicios
de Alta Tecnología AIP, Panama
Co-founder
Co Representative Director
Neung Suh
Independent
investor and consultant for new business development. Experience in working for
IT Venture International Marketing PL and a major business company New Business
Development Department MG.
She met Sugaya in the United States, Florida,
believed in the potential of his technologies, and developing them together in
Japan.
Director
Bob Hering
United States Marine Corps
Colonel
Former founder and CEO, Con-Air Industries
Director
Mohtashem Samsam, MD, PhD
Director
of Research
Advent Health,
Research Institute, Orlando, Florida
Director
David Francis Leon
Lawyer,
The Florida Bar
Partner
Nelson Mullins Broad and Cassel
Outside director
Kyohei Tanaka CPA.
He is a certified accountant. He led a number of M & A deals such as business integration and acquisition of overseas companies at the investment banking headquarters of a major foreign securities company. Then he moved to a private equity company and engaged in investment business. He established investment hub Co., Ltd. independently in 2018. In 2021, he joined Progenicyte Japan Co., Ltd. As an outside director.
Location